Orchard Therapeutics Q2 EPS $(0.07) Beats $(1.67) Estimate, Sales $7.31M Beat $5.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
Orchard Therapeutics reported Q2 earnings per share (EPS) of $(0.07), beating the analyst consensus estimate of $(1.67) by 95.81%. The company also reported quarterly sales of $7.31 million, surpassing the analyst consensus estimate of $5.20 million by 40.65%. Both EPS and sales figures represent significant increases over the same period last year.
August 04, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Orchard Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Orchard Therapeutics reported Q2 earnings and sales that significantly beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100